Nautilus Biotechnology (NAUT) investor relations material

Industry challenges and market opportunity

• Global pharma spends $300B annually on R&D, with 90% of drug programs failing due to limited understanding of proteins and inefficient measurement technologies.

• Current protein analysis methods, including mass spectrometry and assays, provide incomplete, inconsistent, and biased data, hampering drug development and precision medicine.

• Proteins are central to disease mechanisms, but existing platforms can only quantify a fraction of the proteome, limiting AI and biomedical advances.

• The proteomics market is projected to reach $57B by 2030, with significant expansion potential as new technologies unlock broader access.

Technological innovation and platform differentiation

• Nautilus Biotechnology developed a novel iterative mapping approach, enabling high-precision, single-molecule protein identification using hundreds of antibody interactions and advanced computation.

• The platform immobilizes 10 billion intact protein molecules for simultaneous analysis, leveraging proprietary machine learning algorithms for robust, AI-ready data.

• This technology offers broad-scale proteomics and targeted proteoform analysis, initially focusing on the Tau protein implicated in Alzheimer's disease.

• The solution is positioned as a fundamental disruption, analogous to Illumina's impact on genomics, rather than an incremental improvement.

Business model, commercialization, and financial outlook

• Initial market entry targets academic and pharmaceutical discovery proteomics, directly competing with mass spectrometry budgets.

• Commercial launch of the platform is expected in late 2026, with instruments priced at $1M and consumables at several thousand dollars per sample.

• Early access phase will precede launch, focusing on generating customer excitement and validating data through collaborations, such as with the Allen Institute.

• The company maintains strong financial health, with $180M in cash and runway through 2027, and has reduced operating expenses by 20% year over year.